The therapeutic potential of psilocybin

H Lowe, N Toyang, B Steele, H Valentine, J Grant, A Ali… - Molecules, 2021 - mdpi.com
The psychedelic effects of some plants and fungi have been known and deliberately
exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal …

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

JJ Breeksema, BW Kuin, J Kamphuis… - Journal of …, 2022 - journals.sagepub.com
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising
results for the treatment of several mental disorders. Before psychedelics become registered …

[HTML][HTML] Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor

K Kim, T Che, O Panova, JF DiBerto, J Lyu, BE Krumm… - Cell, 2020 - cell.com
Hallucinogens like lysergic acid diethylamide (LSD), psilocybin, and substituted N-benzyl
phenylalkylamines are widely used recreationally with psilocybin being considered as a …

[图书][B] Philosophy of psychedelics

C Letheby - 2021 - books.google.com
Recent clinical trials show that psychedelics such as LSD and psilocybin can be given safely
in controlled conditions, and can cause lasting psychological benefits with one or two …

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

SB Goldberg, BT Pace, CR Nicholas, CL Raison… - Psychiatry …, 2020 - Elsevier
The current meta-analysis examined the effects of psilocybin in combination with behavioral
interventions on anxiety and depression in samples with elevated symptoms. Across four …

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

NL Galvão-Coelho, W Marx, M Gonzalez, J Sinclair… - …, 2021 - Springer
Rationale Major depressive disorder is one of the leading global causes of disability, for
which the classic serotonergic psychedelics have recently reemerged as a potential …

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

W Duan, D Cao, S Wang, J Cheng - Chemical Reviews, 2023 - ACS Publications
Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …

[HTML][HTML] Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders

SB Sartori, N Singewald - Pharmacology & therapeutics, 2019 - Elsevier
Current medication for anxiety disorders is suboptimal in terms of efficiency and tolerability,
highlighting the need for improved drug treatments. In this review an overview of drugs …

Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms

RG Dos Santos, JEC Hallak - Neuroscience & Biobehavioral Reviews, 2020 - Elsevier
Serotoninergic hallucinogens include drugs such as lysergic acid diethylamide (LSD),
dimethyltryptamine (DMT) and psilocybin. Recent trials with single/few doses of these …

Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States

AK Davis, G Agin-Liebes, M España… - … of psychoactive drugs, 2022 - Taylor & Francis
Psychologists are a vital component of mental health treatment and their perceptions of
psychedelic-assisted therapy are critical for future implementation. This cross-sectional …